Pharmacist-led group visits for chronic disease management
Chronic conditions rarely fit neatly into a brief appointment. Patients may need repeated medication reviews, practical self-management education and ongoing encouragement, while short consultations leave little room to explore the barriers affecting their daily lives. A group format creates time for shared learning while preserving individual clinical review. It suits selected patients whose conditions are stable enough for education and peer support, provided clear referral pathways remain in place.
The pharmacist-led group visit model for chronic disease management brings people with a shared condition together for scheduled sessions led by a pharmacist. Participants receive structured information, check their understanding and develop realistic action plans, with individual follow-up where needed. This approach uses the accessibility and continuity of community pharmacy while strengthening links with general practice, allied health services and local consumer organisations.
Why group visits suit chronic care
A useful group is defined by a clinical purpose rather than simply a shared diagnosis. A session might address type 2 diabetes, hypertension, asthma or cardiovascular risk, with each participant completing a personal assessment and setting an individual goal. Shared teaching then provides efficient opportunities to discuss medicines, nutrition, movement, monitoring and warning signs.
For stable chronic conditions, familiarisation with other participants can normalise practical difficulties such as medication side effects, forgotten doses or difficulty navigating lifestyle advice. Peer exchange often provides perspective that a short consultation cannot. Facilitation matters, though: an unstructured conversation can drift, dominant voices can overshadow others and clinical advice can become blurred.
The aim is not to replace personal care with collective instruction. Every participant should have a confidential check-in, a medication review appropriate to their circumstances and a documented plan. Questions requiring diagnosis, prescription changes or detailed interpretation of test results should be handled individually. Group visits work best as an organised component of routine chronic care.
Designing a clear visit pathway
Before the first session, the pharmacist should confirm the participant’s condition, current medicines, allergies, recent results and care arrangements. A pre-visit questionnaire can identify goals, access needs and practical obstacles, while an individual appointment provides the opportunity to address sensitive concerns. Participants should understand what the session covers, how their information is handled and when they will receive follow-up.
A typical session might include a brief health and medication check, short individual planning, one or two focused education topics and a closing action step. Participants can practise skills such as reading a blood glucose record, checking an inhaler or preparing a medication list. Reinforcement through reminders, repeat sessions and a simple action plan is generally more valuable than distributing a large volume of printed material.
The physical setting can influence participation. A Melbourne inner-suburban pharmacy may use its consultation room for small-group appointments, making a service that already sits close to where people shop or collect prescriptions easier to access. In western Sydney, where many communities use multiple languages, professional interpreters and culturally appropriate materials may be essential for informed consent and safe counselling.
Keeping care safe and clinically governed
Clinical governance should define the pharmacist’s role, the scope of each session and the criteria for referral. State legislation determines what pharmacists may prescribe, while delegation and collaborative arrangements must be documented. Any medicine change should follow an agreed protocol identifying who prescribes, who reviews the outcome and when medical follow-up is required.
Monitoring also needs individual attention. Blood pressure, glucose, weight and inhaler technique may be relevant, but measurements and interpretation should remain confidential. Equipment must be maintained and used correctly, and abnormal findings need a defined escalation route. Acute deterioration, suspected complications or significant distress should not wait for the next group session.
Broader medication questions sometimes sit outside the session’s main focus. A patient maintained on valaciclovir may need advice about a new painful mouth lesion; a consumer resource on distinguishing oral herpes lesions can support that conversation, provided pharmacists avoid diagnosing from an image and refer uncertain findings. Ground rules should prohibit identifying disclosures and inappropriate discussion of another participant’s care.
Partnering across the health system
Strong partnerships make a group service useful rather than isolated. General practitioners and practice nurses can identify suitable patients, supply relevant clinical information and receive referral feedback. Dietitians, diabetes educators, mental health professionals, social workers and peer workers can contribute specific expertise without turning every appointment into a crowded multidisciplinary meeting.
The pharmacist should clarify which team member owns each part of the pathway, including routine review, home monitoring, mental health support and social needs. Shared information must be lawful and consented. Participants should know which organisation receives their notes, when a referral will be made and how they can contact the pharmacist between sessions.
Medication access is another area where collaboration adds value. A practitioner account of PrEP and PEP access illustrates how community pharmacies can contribute education and connect people with assessment and care. For eligible Australians, HIV prevention medicines are available through the Pharmaceutical Benefits Scheme, but access also depends on appropriate prescribing, counselling and follow-up.
Building a viable Australian service
A sound business model must identify who pays for group facilitation, preparation, clinical follow-up and administration. The Medicare Benefits Schedule supports eligible chronic disease management services through particular provider arrangements; it should not be assumed that every community pharmacist group session can be billed under an MBS item. Funding may instead involve a general practice, a Primary Health Network, state funding or a locally commissioned service.
Australian prescribing and dispensing arrangements also shape the service. The Pharmaceutical Benefits Scheme influences medicine access, while the Australian Register of Therapeutic Goods provides the regulatory framework for approved medicines. Pharmacists can explain PBS listings, generic options and supply issues, although dispensing data do not reveal whether a patient understands or follows a regimen. Fees, concessions and any consumer charges should be explained before enrolment.
Workforce design is equally important. The lead pharmacist needs protected preparation time, support for covering clinical duties and access to appropriate supervision. Staff require training in group facilitation, health literacy, trauma-informed care and cultural safety. Co-design with Aboriginal and Torres Strait Islander communities should follow local governance arrangements, and participation by community members should be resourced rather than treated as unpaid consultation.
Comparing group and individual care
Group delivery is most appropriate when patients have stable conditions, benefit from shared education and can participate meaningfully in a group. Individual reviews remain preferable when communication needs are complex, privacy is essential or treatment decisions require uninterrupted attention. A combined service can use groups for common education while reserving one-to-one consultations for assessment and individual planning.
Neither format is automatically cheaper or more effective. Outcomes depend on patient selection, facilitator competence, follow-up and the surrounding pathway. The practical differences can be expressed through a direct comparison of their purpose, efficiency, strengths and safeguards.
| Feature | Pharmacist-led group visit | Individual clinical review |
|---|---|---|
| Primary purpose | Shared education, peer learning and self-management support with personal planning | Focused assessment, treatment decisions and private counselling |
| Delivery efficiency | Shared teaching can serve several patients in one session | Each patient receives a complete appointment |
| Main strength | Social support and practical learning from peers | Greater privacy, flexibility and concentration on complex needs |
| Main limitation | Group dynamics require careful facilitation and confidentiality | Offers less peer support and may take longer per patient |
| Clinical safeguard | Individual goals, medication review, referral and documentation for every participant | The same governance, documentation and referral standards apply |
Build the first local pathway
Start with a defined condition, eligible patient group and clinical objective. A pilot might involve one condition, a small number of participants and a short series of sessions supported by a named general practice or Aboriginal health service. Consumer representatives should help choose the topics, session length and outcome measures, ensuring that the service addresses practical barriers rather than a predetermined education package.
Evaluation should combine clinical, experience and operational measures. These may include blood pressure control, medication understanding, goal attainment, referrals completed, attendance and participant feedback. Individual results should be recorded in the appropriate clinical record, while group outcomes should be reported only in aggregated, privacy-protective forms. Comparing results with the service’s baseline can show whether the pathway is working without claiming that every improvement was caused by the group format.
A participating pharmacy can now turn the model into an accessible service: choose one condition, confirm the clinical and funding responsibilities, agree on referral and escalation arrangements with local partners, and set the first group date. Publicising that pathway through the pharmacy, general practice and relevant community networks gives eligible patients a clear route into care while keeping every participant’s clinical decisions personal.